Other OTC - Delayed Quote USD

Astellas Pharma Inc. (ALPMY)

9.55 +0.01 (+0.10%)
At close: April 26 at 3:59 PM EDT

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Mr. Naoki Okamura BSc President, CEO & Director 921.99k -- 1962
Mr. Atsushi Kitamura Chief Financial Officer -- -- --
Nobue Yasuda General Manager of Finance & Accounting Department -- -- --
Mr. Yoshitsugu Shitaka Ph.D. Chief Scientific Officer & Senior Managing Executive Officer -- -- --
Ms. Catherine B. Levitt General Counsel -- -- --
Mr. Katsuyoshi Sugita Chief People Officer, Chief Ethics & Compliance Officer, EVP of HR and Representative Director -- -- 1967
Mr. Stig Ogata Vice President of Corporate Communications -- -- --
Ms. Collette Taylor Senior Vice President of Human Resources -- -- 1963
Ms. Tatjana Dragovic Senior VP and Head of Ethics & Compliance -- -- --
Mr. Nobuaki Tanaka President of Japan Commercial & Senior Corporate Executive -- -- --

Astellas Pharma Inc.

2-5-1, Nihonbashi-Honcho
Chuo-Ku
Tokyo, 103-8411
Japan
81 3 3244 3000 https://www.astellas.com
Sector: 
Healthcare

Description

Astellas Pharma Inc. manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer. It also offers Evrenzo, a treatment for anemia associated with chronic kidney disease; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf and Advagraf/Graceptor/ASTAGRAF XL immunosuppressants. Th company has a research collaboration with Vivtex Corporation to evaluate Vivtex's GI-ORIS screening and formulation platform technology to support the development of novel and oral versions of a therapeutic candidate provided by Astellas; and a partnership agreement with Roche Diabetes Care Japan Co., Ltd. to develop and commercialize integrated diabetes self-management solution. The company was founded in 1923 and is headquartered in Tokyo, Japan.

Corporate Governance

Astellas Pharma Inc.’s ISS Governance QualityScore as of April 1, 2024 is 2. The pillar scores are Audit: 1; Board: 2; Shareholder Rights: 6; Compensation: 1.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

  • Sep 28, 2023
    Ex-Dividend Date
  • Dec 17, 2019
    Dividend Date

Upcoming Events

Related Tickers